Skip to content

Jazz Pharmaceuticals JAZZ Effective Income Tax Rate Reconciliation, FDII, Percent

Effective Income Tax Rate Reconciliation, FDII, Percent at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-4.6%-55.2pp

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent.

The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's effective income tax rate reconciliation, fdii, percent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's effective income tax rate reconciliation, FDII, percent?
Jazz Pharmaceuticals (JAZZ) reported effective income tax rate reconciliation, FDII, percent of -4.6% in Q4 2025.
What does effective income tax rate reconciliation, FDII, percent mean?
The percentage reduction in the effective tax rate due to FDII tax deductions.
How do you interpret effective income tax rate reconciliation, FDII, percent?
A higher percentage indicates a greater tax benefit from foreign-derived income, improving the company's competitive tax position.
How does effective income tax rate reconciliation, FDII, percent compare across companies?
Standard metric for U.S. multinationals to evaluate the impact of international tax incentives.